Share
CytoSorb® is CE-mark approved in the E.U. In the U.S., CytoSorb® and DrugSorb-ATR® are investigational devices not yet FDA authorized/approved/cleared.
Search for ""
Search for ""

Working with Ex Vivo Organ Perfusion to support the management of inflammatory processes

*Not authorized / cleared / approved in the US

 

The ECOS-300CY® is a CE-marked device indicated for the adsorptive removal of specifc cytokines and other inflammatory mediators during ex vivo organ perfusion (EVOP).
 
EVOP is a recently established technique in solid-organ transplantation in which harvested organs — such as the heart, lungs, liver, or kidneys — are perfused with oxygenated, temperature-controlled blood or perfusate outside the body.

Inflammatory mediator adsorption and organ preservation — demonstrated in clinical and preclinical studies.

Removal of IL-6
Reduction of TNF alpha
Versatile application in a variety of organs and EVOP platforms

The ECOS-300CY® Therapy System is a CE marked device specifically approved in the EU for the removal of cytokines and other inflammatory mediators during ex vivo organ perfusion.

ECOS-300CY is a high-flow, low-resistance adsorber designed for easy integration into the perfusate flow of an Ex Vivo Organ Perfusion (EVOP) circuit.
 
The therapy is intended for the adsorptive reduction of certain inflammatory mediators during ex vivo organ perfusion, aiming to support organ conditioning and preservation prior to transplantation.

Viable organs for transplant are scarce and the number of patients awaiting transplant continues to grow globally, with more than 150,000 candidates awaiting transplant in Europe alone. In 2019, 41,000 patients received solid organ transplants in the EU, while 48,000 new patients were added to the transplant list and approximately 4% (or 6,000) died waiting for a transplant.

The combination of Ex Vivo Organ Perfusion (EVOP) with the ECOS300CY® sorbent cartridge represents an emerging approach for supporting organ conditioning and preservation prior to transplantation.
 
Published preclinical and clinical experiences with ex vivo perfusion of solid organs demonstrate the feasibility of integrating hemoadsorption into perfusion circuits and suggest potential benefits for organ preservation and reconditioning.

The ECOS-300CY cartridge is available in the European Union, and also under the brand name PerSorb®, sold in conjunction with the PerLife® perfusion platform by our partner Aferetica.

  • ECOS-300CY is a high-flow, low-resistance adsorber designed for easy integration into the perfusate flow of an Ex Vivo Organ Perfusion (EVOP) circuit.
     
    The therapy is intended for the adsorptive reduction of certain inflammatory mediators during ex vivo organ perfusion, aiming to support organ conditioning and preservation prior to transplantation.

  • Viable organs for transplant are scarce and the number of patients awaiting transplant continues to grow globally, with more than 150,000 candidates awaiting transplant in Europe alone. In 2019, 41,000 patients received solid organ transplants in the EU, while 48,000 new patients were added to the transplant list and approximately 4% (or 6,000) died waiting for a transplant.

  • The combination of Ex Vivo Organ Perfusion (EVOP) with the ECOS300CY® sorbent cartridge represents an emerging approach for supporting organ conditioning and preservation prior to transplantation.
     
    Published preclinical and clinical experiences with ex vivo perfusion of solid organs demonstrate the feasibility of integrating hemoadsorption into perfusion circuits and suggest potential benefits for organ preservation and reconditioning.

  • The ECOS-300CY cartridge is available in the European Union, and also under the brand name PerSorb®, sold in conjunction with the PerLife® perfusion platform by our partner Aferetica.

Additional Information

Download file
  • Refer to the product IFUs for complete information on the warnings, precautions, and contraindications of each device.

    •  

  • IFUs are available on request: > request now
  • Hosgood SA et al., J Transl Med. 2017; 15(1):216
  • Iskender I et al., JTCVS. 2021; 161(2):e109-e121
  • Lindstedt S et al., J Heart Lung Transplant. 2023; 42(10):1358-1362
  • Boffini M et al., Transplant Int. 2023; 36:10777
  • Niromand A et al., Front Cardiovasc Med. 2023; 10:127444

 
ECOS-300CY IFU Indications (11/2022): ECOS is indicated for use during the ex vivo perfusion of harvested organs to remove inflammatory mediators from the perfusion solution by adsorption. ECOS has been shown to reduce levels of inflammatory mediators from Belzer and Steen perfusion solutions. Maximum Treatment Time per Device: 24 hours.

Contact us to learn more about ECOS – 300CY Therapy

Get in touch
NON US & CANADA HEALTHCARE PROFESSIONALS AREA

This section of the website contains medical and clinical information regarding products that are not cleared or approved by the U.S. Food and Drug Administration (FDA) and Health Canada.

Under Canadian and U.S. federal law, including the Federal Food, Drug, and Cosmetic Act, dissemination of information about medical devices that are not FDA/Health Canada cleared or approved for use in the United States or Canada may constitute unlawful promotion or misbranding if directed to U.S. and Canadian healthcare professionals.

 

ACCORDINGLY:

  • This content is intended solely for Healthcare Professionals located outside the United States and Canada.
  • The products described are not approved or cleared in the United States or Canada for any indication.
  • Access by U.S. and Canadian Healthcare Professionals is not permitted.

 

BY PROCEEDING, YOU CONFIRM THAT YOU ARE:
A licensed Healthcare Professional,
located outside the United States and Canada.

Physician experience, clinical practice patterns, risks, and patient outcomes may vary.
The information presented reflects individual clinical experience and does not constitute medical advice.